A Phase 2 interventional study of Pomalidomide in Soft Tissue Sarcoma, sponsored by Celgene. Terminated at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-19.
Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 958 studies in Sarcoma with a site in United States — 153 open to participants now, 244 under way, 4 of them phase 3. Sarcoma · United States.
Among the 958 studies in Sarcoma with a site in United States, this one is the 709th largest by enrollment of the 800 interventional ones that give a count, is one of 28 that started in 2008, is one of 310 in phase 2, and was the 290th registered.
1,609 studies on the registry are indexed under Sarcoma; 367 are open to participants now.
Browse Sarcoma studies →153 of the 958 studies in Sarcoma with a site in United States are open now. Recruiting first, the newest first:
University of Colorado, Denver · Sites in United States
Ages 65–100
M.D. Anderson Cancer Center · Sites in United States
Ages 18–39
Iovance Biotherapeutics, Inc. · Sites in United States
Ages 16–70
St. Jude Children's Research Hospital · Sites in United States
City of Hope Medical Center · Sites in United States
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 302 Sarcoma studies recruiting now, 192 (64%) set no upper age limit and 83 (27%) stop at 75 or younger; 93 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
958 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 393 · Phase 2 426 · Phase 3 42 · Phase 4 4
First in 1983; this study’s year is marked. 28 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 7 is below the median of 41 across 1,254 interventional studies indexed under Sarcoma.
Median enrollment 35 across the 800 interventional studies, 101 across the 100 observational. Of the 650 that completed or were terminated, 245 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
231 of 958 have an industry lead sponsor. The 10 most frequent:
This study is registered under Celgene, one of the names counted as Bristol-Myers Squibb. Under that name alone:
Celgene is the lead sponsor of 428 studies on the registry; 12 are open to participants now.
Of its 104 completed or terminated interventional studies of FDA-regulated products, 30 (29%) have results posted.
Bristol-Myers Squibb has 6 studies filed under Sarcoma — fewer than ten, so there is no comparison to draw.
78 of the studies in Sarcoma with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01223248Phase 3Memorial Sloan Kettering Cancer CenterRandomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy | 2027-10 |
| NCT02307630Memorial Sloan Kettering Cancer CenterPET Imaging of Solid Tumors Using 124I-Humanized 3F8: A Pilot Study | 2026-11 |
| NCT05099666Massachusetts General HospitalLurbinectedin + Doxorubicin In Leiomyosarcoma | 2026-12 |
| NCT03114527Fox Chase Cancer CenterPhase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS) | 2026-12 |
| NCT00582647Memorial Sloan Kettering Cancer CenterCollection of Tissue & Blood From Patients w/ Benign & Malignant Tumors of the Soft Tissue & Gastrointestinal Tract | 2026-12 |
Add all 78 to your calendar (.ics) → With an account.
Among the 958 studies in Sarcoma with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to determine the safety and efficacy of single agent CC-4047 (pomalidomide) in patients with advanced soft tissue sarcomas who have relapsed or are refractory to prior anticancer therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
7 mg pomalidomide taken orally once daily (QD) on days 1 through 21 of each 28-day cycle
Drug: Pomalidomide
Also known as: CC-4047, Pomalyst
Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths, or Discontinuations Due to AEs
An adverse event (AE) is defined as any noxious, unintended, or untoward medical occurrence occurring at any dose that may appear or worsen in a study subject during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the study subject's health, including laboratory test values, regardless of etiology. A serious adverse event (SAE) is defined as any AE which: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; constitutes an important medical event. National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE), Version 3.0, grades: 1 = mild, 2 = moderate, 3 = severe, 4 = life threatening, 5 = death. For more details, please see the Adverse Events section of this record.
Time frame: AEs/SAEs were recorded from informed consent to 30 days post treatment discontinuation visit. Median treatment duration was 49 days (range: 3 to 102 days).
Tumor Response as Assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) Committee Guidelines
Changes in only the longest diameter (LD) of tumor lesions are used in RECIST criteria. Evaluation of target lesions: Complete Response (CR)=Disappearance of all target lesions; Partial Response (PR)=≥30% decrease in sum of the longest diameter (LD) of target lesions taking as reference the baseline sum LD; Progressed Disease (PD)=≥20% increase in sum of LD of target lesions taking as reference the smallest sum LD recorded since treatment started or the appearance of ≥1 new lesions; Stable Disease (SD)=Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD taking as reference the smallest sum LD since treatment started. For non-target lesions: CR= Disappearance of all non-target lesions and normalization of tumor marker level; Incomplete Response/SD=Persistence of ≥1 non-target lesions and/or maintenance of tumor marker level above normal limits; PD=Appearance of ≥1 new lesions; unequivocal progression of existing non-target lesions.
Time frame: Assessed every 8 weeks for the first 8 months and then every 12 weeks thereafter, and at treatment discontinuation. Median treatment duration was 49 days (range: 3 to 102 days).
| Milestone | Pomalidomide |
|---|---|
| Started | 7 |
| Completed | 0 |
| Not completed | 7 |
| Withdrew: Disease progression | 5 |
| Withdrew: Adverse event | 1 |
| Withdrew: Death | 1 |
An adverse event (AE) is defined as any noxious, unintended, or untoward medical occurrence occurring at any dose that may appear or worsen in a study subject during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the study subject's health, including laboratory test values, regardless of etiology. A serious adverse event (SAE) is defined as any AE which: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; constitutes an important medical event. National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE), Version 3.0, grades: 1 = mild, 2 = moderate, 3 = severe, 4 = life threatening, 5 = death. For more details, please see the Adverse Events section of this record.
| participants | Pomalidomide |
|---|---|
| ≥1 AE | 7 |
| ≥1 AE suspected to be related to study drug | 6 |
| ≥1 Grade 3 AE | 4 |
| ≥1 Grade 4 AE | 1 |
| ≥1 SAE | 3 |
| ≥1 SAE suspected to be related to study drug | 1 |
| Death | 4 |
| Death within 30 days of last dose of study drug | 1 |
| Discontinuation due to AE | 2 |
| Dose reduction and interruption due to AE | 1 |
Changes in only the longest diameter (LD) of tumor lesions are used in RECIST criteria. Evaluation of target lesions: Complete Response (CR)=Disappearance of all target lesions; Partial Response (PR)=≥30% decrease in sum of the longest diameter (LD) of target lesions taking as reference the baseline sum LD; Progressed Disease (PD)=≥20% increase in sum of LD of target lesions taking as reference the smallest sum LD recorded since treatment started or the appearance of ≥1 new lesions; Stable Disease (SD)=Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD taking as reference the smallest sum LD since treatment started. For non-target lesions: CR= Disappearance of all non-target lesions and normalization of tumor marker level; Incomplete Response/SD=Persistence of ≥1 non-target lesions and/or maintenance of tumor marker level above normal limits; PD=Appearance of ≥1 new lesions; unequivocal progression of existing non-target lesions.
No measurements were reported for this outcome.
Collected over Treatment-emergent adverse events (TEAEs) are defined as any AE occurring or worsening on or after the first treatment of the study medication and within 30 days after the last dose. Median treatment duration was 49 days (range: 3 to 102 days).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pomalidomide | — | 3/7 (42.9%) | 7/7 (100%) |
| Event | Pomalidomide |
|---|---|
| Cancer PainNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/7 |
| Sarcoma MetastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/7 |
| AnaemiaBlood and lymphatic system disorders | 1/7 |
| Febrile NeutropeniaBlood and lymphatic system disorders | 1/7 |
| LeukopeniaBlood and lymphatic system disorders | 1/7 |
| NeutropeniaBlood and lymphatic system disorders | 1/7 |
| TachycardiaCardiac disorders | 1/7 |
| DysphagiaGastrointestinal disorders | 1/7 |
| MalnutritionMetabolism and nutrition disorders | 1/7 |
| Muscle SpasmsMusculoskeletal and connective tissue disorders | 1/7 |
| Event | Pomalidomide |
|---|---|
| NauseaGastrointestinal disorders | 3/7 |
| AnaemiaBlood and lymphatic system disorders | 3/7 |
| NeutropeniaBlood and lymphatic system disorders | 3/7 |
| ConstipationGastrointestinal disorders | 2/7 |
| Dry mouthGastrointestinal disorders | 2/7 |
| FatigueGeneral disorders | 2/7 |
| ThrombocytopeniaBlood and lymphatic system disorders | 2/7 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 2/7 |
| HypoalbuminaemiaMetabolism and nutrition disorders | 2/7 |
| HypocalcaemiaMetabolism and nutrition disorders | 2/7 |
| Age, Continuous(years) | Pomalidomide |
|---|---|
| Mean | 58.9 ± 13.52 |
| Sex: Female, Male(Participants) | Pomalidomide |
|---|---|
| Female | 3 |
| Male | 4 |
| Race/Ethnicity, Customized(participants) | Pomalidomide |
|---|---|
| White | 7 |
| Non-white | 0 |
Ran from Aug 2008 to primary completion in Jan 2009, 5 months.
Results were first posted in Apr 2013, 4 years 3 months after primary completion. A results delay was requested in Oct 2012.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pomalidomide